The UK will provide the largest ever funding for global surveillance of antimicrobial resistance. Thus, London will launch the second phase of the Fleming Fund’s fight against antimicrobial resistance.
Cutting-edge laboratories, state-of-the-art disease surveillance systems and a larger global workforce to fight deadly antimicrobial resistance (AMR) will be supported with funding of up to £210 million, this announcement announced. the British government on Wednesday.
In a statement received by APA, he explains that the funding, from the UK government’s aid budget, will support the Fleming Fund’s activities to combat antimicrobial resistance in countries in Asia and Africa over the three coming years, helping to reduce the threat it poses to the UK and globally.
The planned funding can reach up to 25 countries with the highest threat and burden of antimicrobial resistance (including Indonesia, Ghana, Kenya and Papua New Guinea) with more than 250 laboratories which need to be upgraded and equipped with state-of-the-art equipment.
This investment includes new genome sequencing technology that will help track bacterial transmission between humans, animals and the environment.
The investment will also strengthen the international healthcare workforce by supporting 20,000 training sessions for laboratory staff, pharmacists and hospital staff, and more than 200 Fleming Fund fellowships to build expertise in microbiology, AMR policy and One Health – which recognizes the connection between humans, animals and the environment.
UK Secretary of State for Health and Social Care Steve Barclay said, “Antimicrobial resistance is a silent killer that poses a significant threat to the health of people around the world and in the UK. It is vital that it is stopped dead in its tracks and this record funding will enable the countries most at risk to tackle it and prevent more casualties around the world, ultimately making us safer at home. . It also builds on the work the government is doing to incentivize pharmaceutical companies to develop new antibiotics.”
He said he was “proud and delighted that the UK’s Fleming Fund continues to create real impact to tackle antimicrobial resistance and strengthen pandemic preparedness on the ground across the world, using data to drive action and catalyze investment”.
This article is originally published on fr.apanews.net